Stock Markets April 15, 2026 09:42 PM

Arxis Prices IPO at $28 a Share, Securing Roughly $1.13 Billion

Bloomfield-based components manufacturer lists on Nasdaq with underwriters granted option to buy extra shares

By Leila Farooq
Arxis Prices IPO at $28 a Share, Securing Roughly $1.13 Billion

Arxis Inc. set its initial public offering price at $28 per share, selling 40.5 million Class A shares to raise about $1.13 billion. The company expanded the offering size and gave underwriters a 30-day option for up to 6.075 million additional shares. Shares are expected to begin trading on the Nasdaq Global Select Market as ARXS on April 16, with the offering anticipated to close on April 17, subject to customary closing conditions.

Key Points

  • Arxis priced its IPO at $28 per share, selling 40.5 million Class A shares to raise approximately $1.13 billion.
  • The company expanded the offering and granted underwriters a 30-day option to buy up to 6.075 million additional shares at the offering price, less underwriting discounts and commissions.
  • Shares are expected to begin trading on the Nasdaq Global Select Market under the symbol ARXS on April 16, with the offering anticipated to close April 17, subject to customary closing conditions; Arxis supplies components to aerospace and defense, medical technology and specialized industrial markets.

Arxis Inc. has priced its initial public offering at $28 per share, the company said April 15. The offering consists of 40.5 million shares of Class A common stock and is expected to generate approximately $1.13 billion in gross proceeds.

Based in Bloomfield, Connecticut, and backed by Arcline Investment Management, Arxis increased the size of the IPO and granted the underwriters a 30-day option to purchase up to an additional 6.075 million shares at the public offering price, less underwriting discounts and commissions. That option can be exercised at the offering price, potentially raising the total number of shares sold if the underwriters choose to do so.

Shares are slated to begin trading on the Nasdaq Global Select Market under the ticker symbol "ARXS" on April 16, with the offering expected to close on April 17, subject to customary closing conditions. Those timing targets are contingent on the completion of normal settlement and closing requirements.

Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as lead joint book-running managers for the transaction. Citigroup and RBC Capital Markets are serving as joint book-running managers. Additional book-running managers include Baird, Guggenheim Securities, Wells Fargo Securities, William Blair, Rothschild & Co and Wolfe | Nomura Alliance. Citizens Capital Markets is serving as a co-manager.

Arxis designs and manufactures electronic and mechanical components intended for customers in aerospace and defense, medical technology and specialized industrial markets. The U.S. Securities and Exchange Commission declared the company’s registration statement on Form S-1 effective on April 15, clearing the way for the offering to proceed.


Bottom line - The IPO brings a significant influx of capital to Arxis and positions the company for public-market trading while leaving a structured option for underwriters to increase the offering size within a 30-day window.

Risks

  • The offering is subject to customary closing conditions, so the expected listing and closing dates are not guaranteed - this affects market timing for investors and issuance settlement.
  • Underwriters have a 30-day option to purchase up to 6.075 million additional shares, which could increase the total shares sold and affect post-offering supply.
  • The announced timetable for trading and closing is contingent on regulatory and settlement processes, leaving potential for timing uncertainty in the Nasdaq listing.

More from Stock Markets

Australian Shares Slip as Healthcare, Financials and Gold Weigh on Index Apr 29, 2026 Fuchs posts Q1 results above forecasts, raises sales outlook for 2026 Apr 29, 2026 Huhtamaki Tops Q1 Expectations but Flags Rising Polymer Costs as Margin Risk Apr 29, 2026 Kambi Holds FY26 EBITA Target Despite €4m Colombia Tax Hit Apr 29, 2026 Pernod Ricard Calls Off Merger Negotiations With Brown-Forman Apr 29, 2026